BrainStorm Cell announces first patient enrollment in Phase II ALS trial BrainStorm Cell announced that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital. BrainStorm's Phase II trial is a randomized, double-blind, placebo controlled multi-center study designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors in 48 ALS patients. The trial is also being conducted at the University of Massachusetts Memorial Hospital and the Mayo Clinic in Rochester, Minnesota.
Piper Jaffray and the Alliance for Regenerative Medicine co-host conference 3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link